London, UK-based Abingworth has raised $315 million for its twelfth life science fund bringing the total amount of funds under management to over $1.2 billion. The new fund, Abingworth Bioventures VII, will invest in companies in Europe and the US.
Abingworth invests across all stages of drug development including early and late-stage venture deals, clinical co-development projects and public equities. The typical investment per company is in the range of $15 to $30 million.